Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LV-Visio-AMTRIX for Resistant Keratitis
NCT05250583Phase 2Terminated
- Sponsor
- TBF Génie Tissulaire
- Start
- Jun 2020
- Primary completion
- Jan 2021
- Modality
- Device-based Delivery, Tissue Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of LV-Visio-AMTRIX in keratitis, sponsored by TBF Génie Tissulaire. Primary endpoint: Keratitis healing within 15 days after the beginning of the treatment. Started Jun 2020; status: terminated.
02
Drugs
LV-Visio-AMTRIX
03
Conditions
keratitis
Beyond the preview
Go deeper on NCT05250583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05250583.